Literature DB >> 28105363

Incidence and survival rates of ovarian cancer in low-income women in Sudan.

Dafalla O Abuidris1, Hsin-Yi Weng2, Ahmed M Elhaj1, Elgaylani Abdallah Eltayeb1, Mohamed Elsanousi3, Rehab S Ibnoof3, Sulma I Mohammed4.   

Abstract

Ovarian cancer is the second most common gynecological cancer worldwide. Little is known about the disease in Sudan. The objective of the present study was to evaluate the incidence rate, age and stage at diagnosis, and median survival time of patients presenting at the National Cancer Institute-University of Gezira (NCI-UG), Sudan. Data were collected in a prospective study of women with ovarian cancer over a period of eleven years of follow-up (between 2000 and 2011). Descriptive statistics were used to summarize the distribution of the demographics of the sample. The direct method was used to compute the age-standardized rate (ASR) using data from the 1966 and 2000 World Standard Populations (WSPs). The Kaplan-Meier method was used to estimate survival functions and the median survival time. Log-rank tests were used to statistically compare between the survival functions. There were steady increases in ovarian cancer incidence rates between 2000 and 2009, with a slight decline noted in 2010 and 2011. The patients' age range was 9-90. The age-specific incidence rate increased greatly in women aged 55 years or older. The majority of the patients had stage III or IV disease. The annual ASR using WSPs 1966 and 2000 as standard populations were 3.3 and 3.7 per 100,000 women, respectively. The median survival time was 31 months (95% confidence interval, 19-43). The 5-year cumulative survival rate was 38%. In Sudan, ovarian cancer affects postmenopausal women, akin to what is reported in the developed world with high incidence rates. Presenting with advanced stage disease is the predominant factor that results in a short survival time for women.

Entities:  

Keywords:  Africa; Gezira State; Sudan; age-standardized rate; ovarian cancer; papillary serrous cystadenocarcinoma; survival

Year:  2016        PMID: 28105363      PMCID: PMC5228336          DOI: 10.3892/mco.2016.1068

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  28 in total

1.  An overview of cancer survival in developing countries.

Authors:  R Sankaranarayanan; R J Black; R Swaminathan; D M Parkin
Journal:  IARC Sci Publ       Date:  1998

2.  Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands.

Authors:  Anne M van Altena; Henrike E Karim-Kos; Esther de Vries; Roy F P M Kruitwagen; Leon F A G Massuger; Lambertus A Kiemeney
Journal:  Gynecol Oncol       Date:  2012-02-24       Impact factor: 5.482

3.  Easy way to learn standardization : direct and indirect methods.

Authors:  N N Naing
Journal:  Malays J Med Sci       Date:  2000-01

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

5.  Ovarian cancer incidence in the United States, 1992-1999.

Authors:  Jeffrey T Quirk; Nachimuthu Natarajan
Journal:  Gynecol Oncol       Date:  2005-05       Impact factor: 5.482

6.  Ovarian cancer in Europe: Cross-sectional trends in incidence and mortality in 28 countries, 1953-2000.

Authors:  Freddie Bray; Anja Helena Loos; Sandro Tognazzo; Carlo La Vecchia
Journal:  Int J Cancer       Date:  2005-03-01       Impact factor: 7.396

7.  A clinico-pathological study of ovarian tumors in Yaounde-Cameroun.

Authors:  A S Doh; W Shasha
Journal:  West Afr J Med       Date:  1994 Oct-Dec

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  Ovarian cancer: an analysis of forty-four patients at the National Radiotherapy Centre, Accra--Ghana.

Authors:  V Vanderpuye; J Yarney
Journal:  West Afr J Med       Date:  2007 Apr-Jun

10.  Incidence, pattern and management of ovarian cancer at a tertiary medical center in enugu, South East Nigeria.

Authors:  Ca Iyoke; Go Ugwu; Ec Ezugwu; N Onah; O Ugwu; O Okafor
Journal:  Ann Med Health Sci Res       Date:  2013-07
View more
  4 in total

1.  Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP/PKA/CREB-FtMt signalling axis.

Authors:  Shipeng Gong; Yongning Chen; Fanliang Meng; Yadi Zhang; Chanyuan Li; Guangping Zhang; Wu Huan; Fei Wu
Journal:  Cell Prolif       Date:  2018-08-02       Impact factor: 6.831

2.  Clinical Characteristics and Survival of Patients with Malignant Ovarian Tumors in Addis Ababa, Ethiopia.

Authors:  Swantje Piszczan; Dawit Desalegn; Hezkiel Petros; Mengistu Gurmu; Eric Sven Kroeber; Adamu Addissie; Rafael Mikolajczyk; Rahel G Ghebre; Assefa Mathewos; Christoph Thomssen; Ahmedin Jemal; Eva Johanna Kantelhardt
Journal:  Oncologist       Date:  2019-04-25

3.  Adverse events of opioids for cancer-related pain in a resource-limited setting: a cross-sectional study from Sudan.

Authors:  Moawia Mohammed Ali Elhassan; Amal Abdulbagi Abdulfatah Mohammed; Amnah Abdulazeem Omer; Arafa Ahmed Mohammed Azeem; Hiba Mohammed Abdelkfi Mohammed; Isra Elameen Mustafa Ibrahim; Nashwa Abdelaziz Abdelrheem Ahmed
Journal:  Ecancermedicalscience       Date:  2022-03-24

4.  Ovarian Cancer: Tumor-Specific Urinary Micro-Peptides Profiling as Potential Biomarkers for Early Diagnosis.

Authors:  Sulafa S Murgan; Faisal J Abd Elaziz; Abubakr M A Nasr; Mona E E Elfaki; Eltahir A G Khalil
Journal:  Proteomes       Date:  2020-10-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.